iTeos Therapeutics signs US$2.75 B Agreement with GlaxoSmithKline
By Ashish Tripathi
Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)
Published: 28 Jul-2021
DOI: 10.3833/pdr.v2021.i7.2629 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its oncology pipeline, GlaxoSmithKline (GSK) has entered into a collaboration agreement with iTeos Therapeutics to develop and commercialise the latter’s monoclonal antibody, EOS-448, for the treatment of advanced solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS